Transfected Stable Cell Lines
Reliable | High-Performance | Wide Rage
Precision reporter, kinase, immune receptor, biosimilar, Cas9, and knockout stable cell lines for diverse applications.
GMP plasmid DNA manufacturing tailored to viral vector production, with construct optimization, process development, scalable fermentation and quality-controlled release for lentiviral and AAV applications.
1–100 L
Fermentation scale
>1-5 g/L
Volumetric yield
≥90%
Supercoiled content
≤0.01 EU/µg
Endotoxin
In cell and gene therapy, the plasmid is the first lot you release and the cheapest place to fix a problem. It is also where problems hide: a truncated ITR, 0.05 EU/µg of endotoxin, or one drifted base in a packaging gene. None of it shows up on a gel or a quick A260 reading — it surfaces months later as low titer, empty capsids or a failed release.
Titer that quietly drops
Nicked or linearized plasmid, or a packaging gene that no longer matches the reference, reduces transfection efficiency before any process parameter changes.
Empty capsids
ITRs are 145 bp palindromic repeats that delete during E. coli propagation. A truncated ITR still grows and still yields DNA — it just packages badly.
Release under pressure
Endotoxin, host DNA or identity failures force a repeat lot exactly when your vector slot is already booked. The recovery cost is schedule, not reagent.
Different vector manufacturing platforms require different plasmid configurations and quality attributes. We tailor construct evaluation, process development and release strategies to the requirements of each program.
Applications: Ex vivo CAR-T, TCR-T, and in vivo LV-delivered CAR
Lentiviral vector production commonly involves transfer, gag-pol, rev and envelope plasmids. Their sequence identity, concentration and topology should be consistently controlled to support reproducible multi-plasmid transfection.
Key Manufacturing Considerations

Applications: Gene therapy and AAV-delivered in vivo CAR-T
AAV manufacturing commonly uses an ITR-containing transfer plasmid, a rep/cap plasmid and a helper plasmid. Maintaining ITR integrity is a key consideration during plasmid propagation and manufacturing.
Key Manufacturing Considerations

Applications: Vector-based AAV or targeted LV delivery
In vivo CAR-T programs require plasmid manufacturing strategies aligned with the selected delivery platform, such as AAV or lentiviral vectors. Construct design, vector compatibility, supply requirements and CMC documentation should be evaluated together.
Key Manufacturing Considerations

Same platform, different critical attributes. Use this to check whether our release strategy matches the failure mode you are actually trying to avoid.
| Program | Plasmid set | Attribute that decides performance | How we control it | Typical scale |
|---|---|---|---|---|
| Ex vivo CAR-T / TCR-T (LV) | Transfer + gag-pol + rev + VSV-G | Supercoiled fraction, packaging-gene fidelity, matched concentration across the set | Four-plasmid co-release, full sequencing, low-copy rescue, DNase-free | 100 mg – 1 g |
| AAV gene therapy | ITR transgene + rep/cap + helper | ITR integrity, backbone size, host DNA | ITR-stabilising strains, low-copy expansion, ITR ≥95% release limit | 100 mg – 2 g |
| In vivo CAR-T (AAV) | ITR CAR cassette + capsid + helper | ITR integrity at scale, lot-to-lot consistency, documentation depth | Gram-scale campaign, ICH stability, DMF modules, change control | 1 – 5 g |
| In vivo CAR-T (LV) | Transfer + packaging + envelope | Envelope and LTR fidelity, endotoxin, supply continuity | Matched sets, backup capacity, tech transfer package | 1 – 5 g |
Scale ranges are indicative and depend on construct size, copy number and downstream vector demand. Minimum campaign starts at 1 L fermentation.
You keep one project manager and one quality contact from intake to CoA. Construct feasibility is decided before any GMP material is committed, so surprises stay in the development phase where they are cheap.
Tech transfer
Send the existing plasmid and its documentation. We audit, qualify and scale what you already have.
Rescue & re-clone
Unstable, low-yield or oversized constructs re-cloned into a production backbone before GMP.
Design to GMP
Construct design, gene synthesis, strain selection and GMP manufacture in one accountable chain.
01
Construct intake & gap review
1–2 weeks
Sequence and restriction audit, strain compatibility, ITR/LTR stability risk, rescue plan and quotation.
02
Seed & strain optimisation
2–3 weeks
Growth and plasmid-stability screening, low-copy rescue, research-grade lot for downstream checks.
03
MCB / WCB establishment
3–4 weeks
Two-tier banking with identity, purity, viability and stability qualification; full documentation.
04
Process development & scale-up
2–4 weeks
Lysis, TFF and AEX/HIC development; yield and impurity DOE; scale-down model qualified.
05
GMP fermentation & purification
2–3 weeks
1–100 L single-use fermentation, closed processing, Grade A isolator fill-finish.
06
QC release & QA disposition
2–3 weeks
Full release panel, CoA, batch record review, stability initiation and shipment.
Indicative durations for a first-time program; stages 03–05 overlap where the construct allows. GMP manufacture and QC release alone typically run 4–6 weeks, consistent with our standard 1–2 month GMP delivery window for constructs with a qualified cell bank and established process. The confirmed schedule is issued with the quality agreement.
Plasmid quality is assessed through a combination of identity, structural integrity, purity, microbiological and physicochemical testing. Analytical methods and acceptance criteria are selected according to the plasmid construct, manufacturing process and intended downstream application.
| Parameter | Method | Typical limit | Why it matters downstream | |
|---|---|---|---|---|
| Identity & structure | Insert identity | Sanger + NGS | 100% match | Correct transgene and regulatory element sequence |
| Restriction map | RE digest | Matches reference | Structural integrity across the whole construct | |
| AAV ITR integrity | RE digest + sequencing | ≥95% | Packaging efficiency and full:empty ratio | |
| LV LTR / RRE integrity | Sequencing | 100% match | Titer and recombination-risk control | |
| Physicochemical | Appearance | Visual inspection | Clear, particle-free | Particulate load entering transfection |
| Concentration | UV A260 | 0.5–3.0 mg/mL, set per project | Accurate molar ratios in multi-plasmid transfection | |
| Supercoiled content | HPLC / CGE | ≥90.0% | Transfection efficiency and vector genome delivery | |
| A260/280 | UV | 1.8–2.0 | Protein carryover | |
| A260/230 | UV | ≥2.0 | Salt and organic carryover | |
| Purity & safety | Endotoxin | LAL | ≤0.01 EU/µg (≤0.005 available) | Cell viability, innate immune activation, in vivo tolerability |
| Host cell DNA | qPCR | ≤5% | Immunogenicity and transfection interference | |
| Host cell RNA | Fluorescence / gel | Non-detectable (≤500 ng) | Purity and nuclease sensitivity | |
| Residual protein | BCA / UV | ≤1% | Stability and aggregate formation | |
| Antibiotic residue | ELISA | <1.125 ng/mL | Compatibility with cell therapy manufacturing | |
| Animal-origin components | Documentation | None used; statement per lot | Viral safety and TSE/BSE risk | |
| TSE / BSE | Certificate | Compliant | Global regulatory acceptance | |
| Microbiology | Sterility | Membrane filtration | No growth, 48 h | Aseptic release for cell culture use |
| Mycoplasma | Culture / qPCR | Negative | Regulatory requirement for cell-based processes |
A plasmid that cannot be defended in an IND is not a GMP plasmid. Every lot ships with the records your CMC team, your vector CDMO and your reviewer will ask for — in the format they expect.
Cell banks
MCB / WCB establishment
Two-tier banking with identity, purity, viability and stability qualification, plus release summaries.
Lot records
Batch records & QA disposition
Executed GMP batch records, deviation and CAPA records, and QA release by lot.
Release
CoA, CoC and release package
Certificate of analysis and conformity, with raw data traceability to instrument level.
Analytics
Method qualification & validation
Qualified and validated methods with transferable protocols for your QC lab or CDMO.
Stability
ICH Q1A stability program
Real-time and accelerated conditions, with annual commitment and protocol-based pull points.
Filing
DMF / eCTD Module 3 support
Authoring and review support for plasmid sections referenced in your IND, BLA or MAA.
Transfer
Tech transfer package
Process description, SOPs, equipment list, method protocols and on-site support if required.
Governance
Quality & supply agreements
QTA/MSA, formal change control, audit access and long-term supply planning.
Programs supported across FDA, EMA, NMPA, PMDA and MFDS submissions, from pre-IND through commercial supply.